{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone%C2%AE+High-Dose&page=2",
    "query": {
      "intervention": "Fluzone® High-Dose",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone%C2%AE+High-Dose&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone%C2%AE+High-Dose&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T16:41:21.286Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07300085",
      "title": "A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Fluzone® High-Dose (HD) influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-1406 Injection",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 710,
      "start_date": "2025-11-08",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 4,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07300085"
    },
    {
      "nct_id": "NCT05624606",
      "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5410",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Influenza vaccine RIV4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza Standard Dose QIV-SD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Inactivated Influenza High Dose QIV-HD",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 682,
      "start_date": "2022-11-28",
      "completion_date": "2024-03-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 23,
      "location_summary": "Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05624606"
    },
    {
      "nct_id": "NCT05050318",
      "title": "Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 90,
      "start_date": "2021-09-08",
      "completion_date": "2021-11-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 2,
      "location_summary": "Bardstown, Kentucky • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05050318"
    },
    {
      "nct_id": "NCT05947071",
      "title": "High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunization; Infection",
        "Transplantation Infection",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Standard Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 312,
      "start_date": "2024-09-26",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 10,
      "location_summary": "Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05947071"
    },
    {
      "nct_id": "NCT05650554",
      "title": "Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5413",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Standard Dose Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza High-Dose Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 682,
      "start_date": "2022-12-12",
      "completion_date": "2024-04-02",
      "has_results": false,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 28,
      "location_summary": "Chula Vista, California • Gardena, California • Long Beach, California + 24 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Gardena",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05650554"
    },
    {
      "nct_id": "NCT05007041",
      "title": "Simultaneous RZV and aIIV4 Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain",
        "Quality of Life",
        "Injection Site Reaction",
        "Adverse Drug Event"
      ],
      "interventions": [
        {
          "name": "FLUAD® Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone® High-Dose Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SHINGRIX®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2021-09-21",
      "completion_date": "2023-06-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Durham, North Carolina",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05007041"
    },
    {
      "nct_id": "NCT00391053",
      "title": "Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Orthomyxoviridae Infection",
        "Influenza",
        "Myxovirus Infection"
      ],
      "interventions": [
        {
          "name": "High-Dose Inactivated, Split-Virion Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated, Split-Virion Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 3851,
      "start_date": "2006-10",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 28,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 25 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00391053"
    },
    {
      "nct_id": "NCT00115531",
      "title": "Eldery High Dose TIV 2005",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Trivalent inactivated influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 414,
      "start_date": "2005-04",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2014-12-19",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 5,
      "location_summary": "Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00115531"
    },
    {
      "nct_id": "NCT02908269",
      "title": "Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone High-Dose, vaccine, 2016-2017 formulation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2016-09-15",
      "completion_date": "2016-12-09",
      "has_results": true,
      "last_update_posted_date": "2022-03-29",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 2,
      "location_summary": "Bardstown, Kentucky • Metairie, Louisiana",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02908269"
    },
    {
      "nct_id": "NCT04613206",
      "title": "High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunization; Infection",
        "Transplantation Infection",
        "Influenza",
        "Solid Organ Transplant"
      ],
      "interventions": [
        {
          "name": "High Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 396,
      "start_date": "2021-01-11",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-02T16:41:21.286Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04613206"
    }
  ]
}